These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 11689643)
1. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine. Misumi S; Nakajima R; Takamune N; Shoji S J Virol; 2001 Dec; 75(23):11614-20. PubMed ID: 11689643 [TBL] [Abstract][Full Text] [Related]
2. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4. Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800 [TBL] [Abstract][Full Text] [Related]
3. A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression. Misumi S; Endo M; Mukai R; Tachibana K; Umeda M; Honda T; Takamune N; Shoji S J Biol Chem; 2003 Aug; 278(34):32335-43. PubMed ID: 12771150 [TBL] [Abstract][Full Text] [Related]
4. Effects of immunization with CCR5-based cycloimmunogen on simian/HIVSF162P3 challenge. Misumi S; Nakayama D; Kusaba M; Iiboshi T; Mukai R; Tachibana K; Nakasone T; Umeda M; Shibata H; Endo M; Takamune N; Shoji S J Immunol; 2006 Jan; 176(1):463-71. PubMed ID: 16365439 [TBL] [Abstract][Full Text] [Related]
5. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy. Nakayama D; Misumi S; Mukai R; Tachibana K; Umeda M; Shibata H; Takamune N; Shoji S J Biochem; 2005 Nov; 138(5):571-82. PubMed ID: 16272569 [TBL] [Abstract][Full Text] [Related]
6. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity. Khurana S; Kennedy M; King LR; Golding H J Virol; 2005 Jun; 79(11):6791-800. PubMed ID: 15890918 [TBL] [Abstract][Full Text] [Related]
7. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Baba M; Takashima K; Miyake H; Kanzaki N; Teshima K; Wang X; Shiraishi M; Iizawa Y Antimicrob Agents Chemother; 2005 Nov; 49(11):4584-91. PubMed ID: 16251299 [TBL] [Abstract][Full Text] [Related]
8. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding. Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073 [TBL] [Abstract][Full Text] [Related]
9. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Aarons EJ; Beddows S; Willingham T; Wu L; Koup RA Virology; 2001 Sep; 287(2):382-90. PubMed ID: 11531415 [TBL] [Abstract][Full Text] [Related]
10. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Blanpain C; Vanderwinden JM; Cihak J; Wittamer V; Le Poul E; Issafras H; Stangassinger M; Vassart G; Marullo S; Schlndorff D; Parmentier M; Mack M Mol Biol Cell; 2002 Feb; 13(2):723-37. PubMed ID: 11854425 [TBL] [Abstract][Full Text] [Related]
11. Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides. Zhang Y; Pool C; Sadler K; Yan HP; Edl J; Wang X; Boyd JG; Tam JP Biochemistry; 2004 Oct; 43(39):12575-84. PubMed ID: 15449947 [TBL] [Abstract][Full Text] [Related]
12. A new prospective against HIV infection: induction of murin CCR5-downregulating antibodies. Barassi C; Marenzi C; Pastori C; Longhi R; Lazzarin A; Lopalco L New Microbiol; 2004 Apr; 27(2 Suppl 1):85-94. PubMed ID: 15646069 [TBL] [Abstract][Full Text] [Related]